
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.
Publication
, Journal Article
Burns, TM; Smith, GA; Allen, JA; Amato, AA; Arnold, WD; Barohn, R; Benatar, M; Bird, SJ; Bromberg, M; Chahin, N; Ciafaloni, E; Cohen, JA ...
Published in: Muscle Nerve
February 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Muscle Nerve
DOI
EISSN
1097-4598
Publication Date
February 2016
Volume
53
Issue
2
Start / End Page
165 / 168
Location
United States
Related Subject Headings
- Potassium Channel Blockers
- Physicians
- Orphan Drug Production
- Neuromuscular Junction Diseases
- Neurology & Neurosurgery
- Humans
- Amifampridine
- 4-Aminopyridine
- 32 Biomedical and clinical sciences
- 31 Biological sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Burns, T. M., Smith, G. A., Allen, J. A., Amato, A. A., Arnold, W. D., Barohn, R., … Wolfe, G. I. (2016). Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve, 53(2), 165–168. https://doi.org/10.1002/mus.25009
Burns, Ted M., Gordon A. Smith, Jeffrey A. Allen, Anthony A. Amato, W David Arnold, Richard Barohn, Michael Benatar, et al. “Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.” Muscle Nerve 53, no. 2 (February 2016): 165–68. https://doi.org/10.1002/mus.25009.
Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, et al. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb;53(2):165–8.
Burns, Ted M., et al. “Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.” Muscle Nerve, vol. 53, no. 2, Feb. 2016, pp. 165–68. Pubmed, doi:10.1002/mus.25009.
Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EAD, Donofrio PD, Dyck PJB, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb LD, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou J-S, MacGowen DJL, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon J-S, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb;53(2):165–168.

Published In
Muscle Nerve
DOI
EISSN
1097-4598
Publication Date
February 2016
Volume
53
Issue
2
Start / End Page
165 / 168
Location
United States
Related Subject Headings
- Potassium Channel Blockers
- Physicians
- Orphan Drug Production
- Neuromuscular Junction Diseases
- Neurology & Neurosurgery
- Humans
- Amifampridine
- 4-Aminopyridine
- 32 Biomedical and clinical sciences
- 31 Biological sciences